Special lssues

Cancer Immunotherapy

Submission Deadline: 31 October 2022 (closed)

Guest Editors

Prof. Yi Hu, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences (CAS), Beijing, 100049, China.
Email: huyi@ihep.ac.cn

Prof. Kexin Xu, Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Email: XuK3@uthscsa.edu


The past decade has witnessed the rapid development of immunotherapy against cancer. Versatile therapeutic approaches have been developed to modulate the innate/adaptive immunity and consequently activate the immune system to recognize and kill the cancer cells. Despite its great promise, antitumor immunotherapy still faces multiple challenges for clinical translation. For instance, the immunosuppressive tumor microenvironment help the cancer cell evade or suppress the immuneresponse. In addition, immunotherapy may also elicit severe side effects. 

This Special Issue aims to highlight recent advances in the development of cancer immunotherapy. We highly encourage the eminent scientists, as well as emerging young scientists, in the field of cancer immunotherapy to share their recent research progress or expert opinions in this Special Issue. We welcome contributions in the form of perspectives, reviews or original research articles on the topics of cancer immunotherapy in the following fields but not limited to:


l   PD-1/PD-L1

l   Epigenetics in immunotherapy

l   Nanotechnology-assisted immunotherapy

l   Tumor vaccine

l   Immunotherapy resistance

l   Approaches for predicting responses to immunotherapy

l   Clinical translation of immunotherapy


Immune checkpoint, Epigenetics, Nanotechnology, Vaccine, Immune resistance, Immune response, Clinical translation

Published Papers

  • Open Access


    The Emerging Role of Lymphocyte Activation Gene 3 in the Cancer Immunotherapy

    Xue Cui, Min Peng, Honglei Chen
    Oncologie, Vol.24, No.4, pp. 665-678, 2022, DOI:10.32604/oncologie.2022.023641
    (This article belongs to this Special Issue: Cancer Immunotherapy)
    Abstract The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors, researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory co-receptor that plays a vital role in autoimmunity, cancer immunity, and anti-infection immunity. Immune combination therapy… More >

  • Open Access


    Polarized Autologous Macrophages (PAM) Can Be a Tumor Vaccine

    Dongqing Wang, Heying Chen, Yi Hu
    Oncologie, Vol.24, No.3, pp. 441-449, 2022, DOI:10.32604/oncologie.2022.024898
    (This article belongs to this Special Issue: Cancer Immunotherapy)
    Abstract Immunotherapy is currently recognized as one of the most promising anticancer strategies. In the tumor microenvironment, tumor-associated macrophages are mainly M2-type macrophages with tumor-promoting effects. Therefore, the reprogramming of tumor-associated macrophages from M2 to M1 type is a potential strategy for cancer therapy. We have previously shown the anticancer effects of implantable allogeneic M1 macrophages in mice. Here, we further engineered autologous mouse bone marrow cells into M1 macrophages and then embedded them into a sodium alginate gel to prepare an implantable immunotherapeutic agent (M1@Gel). We demonstrate that M1@Gel repolarizes M2 macrophages to M1 type and activates the immune responses… More >

  • Open Access


    The Transcriptional and Immunological Roles of Six2 in Clear Cell Renal Cell Carcinoma

    Dayu Tian, Yang Shi, Li Lei, Xiangmin Qiu, Tao Song, Qianyin Li
    Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838
    (This article belongs to this Special Issue: Cancer Immunotherapy)
    Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related differentially expressed genes… More >

Share Link